The pharmaceutical industry website FiercePharma reported on April 13th that Bayer will pay roughly $110 million to settle 500 Yaz lawsuits. That works out to an average settlement of $220,000 per case. To put those numbers in perspective, Yaz and Yasmin together are Bayer’s second-highest-grossing drugs, with 2010 revenue of $1.58 billion.
The settlements in this article are only for women who developed blood clots while taking Yaz. Although there is evidence that Yaz can also cause gall bladder problems, Bayer is not settling those cases at this time. Instead, they are settling clotting cases. Perhaps not coincidentally, these settlements come not long after new studies show that Yaz and Yasmin increase the risk of developing blood clots.
As of February, Bayer had only entered into about 70 Yaz settlement agreements. To jump from 70 to 500 clearly shows Bayer wants to resolve these cases.
Comments